<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034306</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-204RA</org_study_id>
    <nct_id>NCT01034306</nct_id>
  </id_info>
  <brief_title>Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will test the hypothesis that the administration of CF101, a novel&#xD;
      anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at&#xD;
      baseline will relieve signs and symptoms of the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled,&#xD;
      study in which patients with active RA and high A3AR expression at baseline will be&#xD;
      randomized to the addition of either CF101 1.0 mg or placebo given orally q12h for 12 weeks.&#xD;
      Screening examinations will occur within 1 month prior to dosing. Washout of other&#xD;
      disease-modifying antirheumatic drugs (DMARDs), including biological agents, will occur prior&#xD;
      to dosing; if washout is necessary, patients must re-qualify for inclusion following the&#xD;
      washout. Doses of nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids must be&#xD;
      stable for &gt;=1 month prior to dosing and remain so during protocol participation. Disease&#xD;
      activity will be assessed using swollen and tender joint counts, physician and patient global&#xD;
      assessments (by visual analog scale, VAS), patient reported pain (by VAS), a Health&#xD;
      Assessment Questionnaire (HAQ) Disability Index (DI), Westergren erythrocyte sedimentation&#xD;
      rate (ESR, Screening, Weeks 0 and12), and C-reactive protein (CRP) levels. Assessments will&#xD;
      take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, and 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR20)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Primary efficacy was assessed using ACR20 response at Week 12, with all-cause dropouts considered as non-responders, in the ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Event Reporting, Physical Examination, Vital Signs, Clinical Laboratory Testing</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CF101 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>orally q12h</description>
    <arm_group_label>CF101 1 mg</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>orally q12 hours</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ages 18-75 years&#xD;
&#xD;
          -  Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al.&#xD;
             Arthritis Rheum 1988;31:315-324, Appendix 1)&#xD;
&#xD;
          -  Not bed- or wheelchair-bound&#xD;
&#xD;
          -  Active RA, as indicated by the presence of (a) &gt;=6 swollen joints (28 joint count);&#xD;
             AND (b) &gt;=6 tender joints (28 joint count); AND either: (c) Westergren ESR of &gt;=28&#xD;
             mm/hour; OR (d) CRP level above the upper limit of normal for the central reference&#xD;
             laboratory&#xD;
&#xD;
          -  Elevated PBMC A3AR expression level, defined as &gt;= 1.5-fold over a predetermined&#xD;
             normal population standard, following the appropriate DMARD/biologic washout period&#xD;
             (see Exclusion Criteria) but within 2 weeks of beginning dosing&#xD;
&#xD;
          -  If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at&#xD;
             least 1 month prior to the A3AR Qualification Visit, and will remain unchanged during&#xD;
             protocol participation&#xD;
&#xD;
          -  If taking an oral corticosteroid, dose is &lt;=10 mg/day prednisone or equivalent, has&#xD;
             been stable for at least 1 month prior to the A3AR Qualification Visit, and will&#xD;
             remain unchanged during protocol participation&#xD;
&#xD;
          -  In the Investigator's opinion, the ability to understand the nature of the study and&#xD;
             any hazards of participation, and to communicate satisfactorily with the Investigator&#xD;
             and to participate in, and to comply with, the requirements of the entire protocol&#xD;
&#xD;
          -  Negative screening serum pregnancy test for female patients of childbearing potential&#xD;
&#xD;
          -  Females of childbearing potential must utilize, throughout the course of the trial, 2&#xD;
             methods of contraception deemed adequate by the Investigator (for example, oral&#xD;
             contraceptive pills plus a barrier method)&#xD;
&#xD;
          -  All aspects of the protocol explained and written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any of the following for at least a 1 month washout period prior to the&#xD;
             A3AR Qualification Visit: methotrexate, sulfasalazine, oral or injectable gold,&#xD;
             azathioprine, minocycline, penicillamine, anakinra&#xD;
&#xD;
          -  Receipt of etanercept for at least a 6 week washout period prior to the A3AR&#xD;
             Qualification Visit&#xD;
&#xD;
          -  Receipt of chloroquine, hydroxychloroquine, cyclosporine, infliximab, golimumab or&#xD;
             adalimumab for at least a 2 month washout period prior to the A3AR Qualification Visit&#xD;
&#xD;
          -  Receipt of leflunomide for at least a 2 month washout period prior to the A3AR&#xD;
             Qualification Visit, unless patient has undergone cholestyramine washout at least 1&#xD;
             month prior to testing&#xD;
&#xD;
          -  Receipt of cyclophosphamide for at least a 6 month period prior to the A3AR&#xD;
             Qualification Visit&#xD;
&#xD;
          -  Receipt of rituximab at any previous time&#xD;
&#xD;
          -  Previous failure to respond to methotrexate or any anti-rheumatic biological agent&#xD;
&#xD;
          -  Participation in a previous trial CF101 trial&#xD;
&#xD;
          -  Use of oral corticosteroids &gt;10 mg of prednisone, or equivalent, per day&#xD;
&#xD;
          -  Change in NSAID dose level for 1 month prior to the A3AR Qualification Visit&#xD;
&#xD;
          -  Change in oral corticosteroid dose level during the 1 month prior to the A3AR&#xD;
             Qualification Visit&#xD;
&#xD;
          -  Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to&#xD;
             the A3AR Qualification Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioStrategics Consulting Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Sofia</city>
        <zip>1359</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sveti Ivan Rilski&quot;, Rheumatoloty Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.canfite.co.il</url>
    <description>Sponsor</description>
  </link>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <results_first_submitted>February 24, 2015</results_first_submitted>
  <results_first_submitted_qc>February 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2015</results_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CF101 1mg</title>
          <description>CF101 1mg q12 for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo q12 for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>hospitalized and decided to stop</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncomplience</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF101 1mg</title>
          <description>CF101 1mg q12 for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>MAtching placebo q12 for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.7" spread="9.87"/>
                    <measurement group_id="B2" value="61.7" spread="6.89"/>
                    <measurement group_id="B3" value="59" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American College of Rheumatology (ACR20)</title>
        <description>Primary efficacy was assessed using ACR20 response at Week 12, with all-cause dropouts considered as non-responders, in the ITT population.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CF101 1mg</title>
            <description>CF101 1mg q12 for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo q12 for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology (ACR20)</title>
          <description>Primary efficacy was assessed using ACR20 response at Week 12, with all-cause dropouts considered as non-responders, in the ITT population.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Adverse Event Reporting, Physical Examination, Vital Signs, Clinical Laboratory Testing</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CF101 1mg</title>
          <description>CF101 1mg q12 for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo q12 for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation with uncontrolled ventricular response</sub_title>
                <description>atrial fibrillation with uncontrolled ventricular response</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyoderma</sub_title>
                <description>Pyoderma</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pnina Fishman, PhD</name_or_title>
      <organization>Can-Fite Biopharma</organization>
      <phone>011972 39241114</phone>
      <email>pnina@canfite.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

